NVAX - Novavax, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
6.01
-0.11 (-1.80%)
As of 11:58AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close6.12
Open6.14
Bid6.04 x 1200
Ask6.05 x 900
Day's Range5.98 - 6.16
52 Week Range5.72 - 51.60
Volume110,855
Avg. Volume1,111,368
Market Cap141.071M
Beta (3Y Monthly)2.12
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Are These 2 Beaten-Down Biotech Stocks Worth the Risk?
    Motley Fool8 days ago

    Are These 2 Beaten-Down Biotech Stocks Worth the Risk?

    Catalyst Pharmaceuticals and Novavax have had tough go of it in May. Could better days be close at hand?

  • Thomson Reuters StreetEvents14 days ago

    Edited Transcript of NVAX earnings conference call or presentation 2-May-19 8:30pm GMT

    Q1 2019 Novavax Inc Earnings Call

  • How Novavax plans to advance after failed drug trial, delisting threat
    American City Business Journals15 days ago

    How Novavax plans to advance after failed drug trial, delisting threat

    The company will put into effect a reverse stock split of its issued and outstanding common stock, a move intended to increase its share price.

  • Why Novavax Stock Is Fading Today
    Motley Fool17 days ago

    Why Novavax Stock Is Fading Today

    Novavax's proposed reverse split has investors on edge.

  • NanoFlu Vaccine Could Be Big Growth Opportunity for Novavax
    Market Realist17 days ago

    NanoFlu Vaccine Could Be Big Growth Opportunity for Novavax

    Is Novavax an Attractive Pick after First-Quarter Results?(Continued from Prior Part)Nanoflu vaccine updatesOn January 3, Novavax (NVAX) issued a press release announcing positive top-line results from a Phase 2 trial that compared multiple

  • Will the ResVax Vaccine Be Key Revenue Driver for Novavax?
    Market Realist18 days ago

    Will the ResVax Vaccine Be Key Revenue Driver for Novavax?

    Is Novavax an Attractive Pick after First-Quarter Results?(Continued from Prior Part)Resvax vaccine updatesOn February 28, Novavax (NVAX) issued a press release announcing results from the first-ever Phase 3 trial for PrepareTM, evaluating the

  • What Analysts Are Recommending for Novavax after Q1 Results
    Market Realist18 days ago

    What Analysts Are Recommending for Novavax after Q1 Results

    Is Novavax an Attractive Pick after First-Quarter Results?Stock price movementsNovavax (NVAX) reported first-quarter results on May 2. The company reported revenues of $3.98 billion in the first quarter, a YoY decline of 58.75% and $0.62 million

  • Here’s What Hedge Funds Think About Novavax, Inc. (NVAX)
    Insider Monkey19 days ago

    Here’s What Hedge Funds Think About Novavax, Inc. (NVAX)

    Billionaire hedge fund managers such as David Abrams, Steve Cohen and Stan Druckenmiller can generate millions or even billions of dollars every year by pinning down high-potential small-cap stocks and pouring cash into these candidates. Small-cap stocks are overlooked by most investors, brokerage houses, and financial services hubs, while the unlimited research abilities of the […]

  • Is Novavax a Buy?
    Motley Fool21 days ago

    Is Novavax a Buy?

    Novavax's first-quarter earnings report didn't provide the answers investors were looking for.

  • Novavax Inc (NVAX) Q1 2019 Earnings Call Transcript
    Motley Fool21 days ago

    Novavax Inc (NVAX) Q1 2019 Earnings Call Transcript

    NVAX earnings call for the period ending March 31, 2019.

  • Novavax (NVAX) Reports Q1 Loss, Misses Revenue Estimates
    Zacks22 days ago

    Novavax (NVAX) Reports Q1 Loss, Misses Revenue Estimates

    Novavax (NVAX) delivered earnings and revenue surprises of 8.33% and -17.04%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press22 days ago

    Novavax: 1Q Earnings Snapshot

    The Gaithersburg, Maryland-based company said it had a loss of 11 cents per share. The results beat Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...

  • Is the Options Market Predicting a Spike in Novavax (NVAX) Stock?
    Zacks22 days ago

    Is the Options Market Predicting a Spike in Novavax (NVAX) Stock?

    Investors need to pay close attention to Novavax (NVAX) stock based on the movements in the options market lately.

  • What's in the Cards for Novavax (NVAX) This Earnings Season?
    Zacks23 days ago

    What's in the Cards for Novavax (NVAX) This Earnings Season?

    Novavax (NVAX) is likely to provide update on the path forward for its two lead vaccine candidates.

  • Zacks Value Trader Highlights: Novavax, J.C. Penney, Pier 1 Imports, Tilray and Aurora Cannabis
    Zacks29 days ago

    Zacks Value Trader Highlights: Novavax, J.C. Penney, Pier 1 Imports, Tilray and Aurora Cannabis

    Zacks Value Trader Highlights: Novavax, J.C. Penney, Pier 1 Imports, Tilray and Aurora Cannabis

  • Should You Buy Lottery Stocks?
    Zackslast month

    Should You Buy Lottery Stocks?

    Like playing the lottery, some stocks lure in investors with the promise of possible riches.

  • Benzingalast month

    The Daily Biotech Pulse: J&J Earnings, FDA Nod For Medicinova, Proteon To Explore Strategic Alternatives

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 15) Amneal Pharmaceuticals Inc (NYSE: AMRX ) Biohaven ...

  • Novavax faces delisting threat following failed drug trial
    American City Business Journalslast month

    Novavax faces delisting threat following failed drug trial

    Nasdaq has warned Novavax Inc. that its stock could be delisted if it can’t get the price consistently above a buck within the next six months. The Gaithersburg biotech’s stock has fallen below $1 for 30 consecutive days and the company has 180 days — until Oct. 8 — to regain compliance by getting its common stock bid price up for at least 10 consecutive business days. Novavax plans to hold a special stockholder meeting May 8 to consider a reverse stock split, according to public filings.

  • Benzingalast month

    The Week Ahead In Biotech: Conferences, Clinical Trial Readouts, Earnings And IPOs

    Biotech stocks witnessed a slowdown in momentum last week, which was a relatively slow one in terms of news flow. Amgen, Inc. (NASDAQ: AMGN )'s unique drug to treat osteoporosis in postmenopausal women ...

  • Novavax (NVAX) Stock Moves -0.67%: What You Should Know
    Zackslast month

    Novavax (NVAX) Stock Moves -0.67%: What You Should Know

    In the latest trading session, Novavax (NVAX) closed at $0.57, marking a -0.67% move from the previous day.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of NVAX earnings conference call or presentation 18-Mar-19 8:30pm GMT

    Q4 2018 Novavax Inc Earnings Call

  • Novavax (NVAX) Outpaces Stock Market Gains: What You Should Know
    Zacks2 months ago

    Novavax (NVAX) Outpaces Stock Market Gains: What You Should Know

    In the latest trading session, Novavax (NVAX) closed at $0.59, marking a +1.57% move from the previous day.

  • Novavax (NVAX) Gains As Market Dips: What You Should Know
    Zacks2 months ago

    Novavax (NVAX) Gains As Market Dips: What You Should Know

    In the latest trading session, Novavax (NVAX) closed at $0.53, marking a +0.21% move from the previous day.

  • 3 Cheap Stocks to Buy That Are Worth Every Penny
    InvestorPlace2 months ago

    3 Cheap Stocks to Buy That Are Worth Every Penny

    So close, and yet so far. That sums up the state of the markets recently, with investors jittery over the sudden chill surrounding U.S.-China relations. In an about-face on the trade dispute, President Trump conceded that tariffs on Chinese goods may remain for a "substantial period of time." Simultaneously, this hurts the broader markets but it also raises prospects for cheap stocks.I know what you're thinking: why should I consider cheap stocks to buy when blue-chip names are also available for deeply discounted prices? Far be it from me to disagree with that logic. Typically, you accrue the biggest profits from striking while others are panicking. But after you're comfortable with your high-probability bets, penny stocks provide exceptionally robust return potential.We should also discuss the "under-the-radar" argument. News such as the trade-war dispute disproportionately hurt the blue chips because they're usually multinational corporations with global vulnerabilities. While penny stocks also suffer the trickle-down effect, they're more likely to move on sector-specific developments.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * The 10 Best ETFs to Buy in the Second Quarter With that in mind, let's take a look at three (very) cheap stocks to buy that are worth every penny: Entree Resources (EGI)Source: Jeremy Vohwinkle via Flickr (Modified)Entree Resources (NYSEAMERICAN:EGI) is one of the penny stocks that actually benefits from broader and sector-specific trends. With all eyes focused on the suddenly deteriorating trade-war dispute, investors get nervous. When investors get nervous, they buy gold. Naturally, as a gold miner, EGI has a lot to gain.Another thing that intrigued me about EGI as a candidate for cheap stocks to buy is its locality. Most speculative miners have projects in extremely unstable countries just begging for nationalization. While Entree's main property in Mongolia isn't the greatest region for stability, it's also not the worst. Over the last few years, Mongolia improved its standing for ease of doing business.Additionally, the gold price has also improved, gaining roughly 10% since the first of October. That's a net positive for EGI stock, especially since it might go higher still. However, keep in mind that gold is extremely volatile, so don't lever yourself excessively. Genius Brands International (GNUS)Source: Shutterstock The entertainment industry is a tough sector in which to survive, let alone thrive. What works and what doesn't often seem arbitrary. Moreover, maintaining relevance is a gargantuan task once you've accomplished the already difficult task of delivering a hit. But the prospect of finding that hit drives Genius Brands International (NASDAQ:GNUS).GNUS specializes in creating compelling content and characters. Where it differs compared to other cheap stocks in the entertainment field is the company's core audience: toddlers to tweens. This is an exceptionally challenging market to crack because you're dealing with two audiences: the young consumer and their parents/guardians. * 10 Stocks on the Rise Heading Into the Second Quarter At the same time, GNUS has a viable pathway to profound growth. The reason? Brands such as cartoon characters translate very well internationally. If it resonates in America, it will probably resonate everywhere else. Novavax (NVAX)Source: Shutterstock Over the past few years, vaccination captured the public's attention, and not always in a good way. With President Trump's election, an increasing number of people became aware of so-called alternative-truth movements. Many of these right-leaning organizations rally fiercely against vaccination, particularly government-imposed protocols.On the surface, that doesn't help Novavax (NASDAQ:NVAX), which specializes in the stuff. Nor does the fact that NVAX is one of the riskiest penny stocks to buy. Since Feb. 27, shares have plummeted nearly 71%. Even more concerning is the reason why NVAX fell.In a clinical trial, the company's NanoFlu treatment failed to beat placebo. In other words, positive thinking yielded roughly the same efficacy in preventing influenza than the vaccine.Given that NVAX is a fundamentally poor organization, I'm not surprised that shares fell. However, keep in mind that most Americans support vaccination. Therefore, the broader financial incentive to stay the course until efficacy improves is incredibly high.As of this writing, Josh Enomoto is long gold. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Retail Stocks That Will Continue to Rebound in 2019 * 5 Stocks To Buy for the Happiest Employees * 7 ETFs for a Millennial Portfolio Compare Brokers The post 3 Cheap Stocks to Buy That Are Worth Every Penny appeared first on InvestorPlace.